{"id":"NCT00172185","sponsor":"Shire","briefTitle":"Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","officialTitle":"A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01-10","primaryCompletion":"2008-01-24","completion":"2008-01-24","firstPosted":"2005-09-15","resultsPosted":"2013-04-23","lastUpdate":"2021-06-02"},"enrollment":65,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Short Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"teduglutide 0.05 mg/kg/d","otherNames":["GATTEX"]},{"type":"DRUG","name":"teduglutide 0.10 mg/kg/d","otherNames":["GATTEX"]}],"arms":[{"label":"teduglutide 0.05 mg/kg/d","type":"EXPERIMENTAL"},{"label":"teduglutide 0.10 mg/kg/d","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.","primaryOutcome":{"measure":"Number of Subjects Achieving a 20% Reduction at Week 28","timeFrame":"28 weeks","effectByArm":[{"arm":"Placebo/0.05","deltaMin":5,"sd":null},{"arm":"Placebo/0.10","deltaMin":3,"sd":null},{"arm":"0.05/0.05","deltaMin":17,"sd":null},{"arm":"0.10/0.10","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":21,"countries":["United States","Belgium","Canada","Denmark","France","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["21317170","23333663","24134154"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":6},"commonTop":["Headache","Abdominal pain","Skin and subcutaneous tissue disorder","Nausea","Nasopharyngitis"]}}